Literature DB >> 12874772

Acute parvovirus B19 infection associated with myocarditis in an immunocompetent adult.

Steffen Lamparter1, Michael Schoppet, Sabine Pankuweit, Bernhard Maisch.   

Abstract

Inflammatory heart disease is causally linked with progressive left ventricular dysfunction and congestive heart failure. In childhood, infection with parvovirus B19 (PVB19) is usually benign, causing erythema infectiosum. However, severe fetal PVB19 infection may be associated with hydrops fetalis and fetal death caused by myocarditis. Here we report a PVB19-induced myocarditis in a previously healthy 37-year-old patient admitted to the hospital because of chest pain and dyspnea due to left ventricular dysfunction. Four weeks after the onset of symptoms, we found lymphocytic infiltrates and PVB19 genome in left ventricular endomyocardial biopsy specimens. Consistently, acute PVB19 infection was indicated serologically by elevated IgM titers and the presence of PVB19 genome in peripheral blood lymphocytes. In conclusion, PVB19 infection may be complicated by acute myocarditis in immunocompetent adults. Because PVB19 myocarditis may progress to chronic dilated cardiomyopathy, early diagnosis by endomyocardial biopsy is important to initiate anti-inflammatory treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12874772     DOI: 10.1016/s0046-8177(03)00235-1

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  10 in total

1.  Myocardial parvovirus B19 persistence: lack of association with clinicopathologic phenotype in adults with heart failure.

Authors:  Garrick C Stewart; Javier Lopez-Molina; Raju V S R K Gottumukkala; Gregg F Rosner; Mary S Anello; Jonathan L Hecht; Gayle L Winters; Robert F Padera; Kenneth L Baughman; Myra A Lipes
Journal:  Circ Heart Fail       Date:  2010-11-19       Impact factor: 8.790

Review 2.  Current treatment options in (peri)myocarditis and inflammatory cardiomyopathy.

Authors:  B Maisch; S Pankuweit
Journal:  Herz       Date:  2012-09       Impact factor: 1.443

Review 3.  Human Parvoviruses.

Authors:  Jianming Qiu; Maria Söderlund-Venermo; Neal S Young
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

Review 4.  Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives.

Authors:  Bernhard Maisch; Sabine Pankuweit
Journal:  Heart Fail Rev       Date:  2013-11       Impact factor: 4.214

Review 5.  [Viral exanthem].

Authors:  R Fölster-Holst
Journal:  Hautarzt       Date:  2004-09       Impact factor: 0.751

6.  Human parvovirus B19 associated dilated cardiomyopathy.

Authors:  Parul Jain; Amita Jain; Danish Nasar Khan; Mala Kumar
Journal:  BMJ Case Rep       Date:  2013-08-05

7.  The presence of enterovirus, adenovirus, and parvovirus B19 in myocardial tissue samples from autopsies: an evaluation of their frequencies in deceased individuals with myocarditis and in non-inflamed control hearts.

Authors:  Trine Skov Nielsen; Jakob Hansen; Lars Peter Nielsen; Ulrik Thorngren Baandrup; Jytte Banner
Journal:  Forensic Sci Med Pathol       Date:  2014-04-30       Impact factor: 2.456

8.  Fatal parvoviral myocarditis: a case report and review of literature.

Authors:  Fabio Tavora; Luis F Gonzalez-Cuyar; Jay S Dalal; Michael T O'Malley; Richard Zhao; Hong Q Peng; Allen P Burke
Journal:  Diagn Pathol       Date:  2008-04-30       Impact factor: 2.644

9.  The Impact of Human Parvovirus B19 Infection on Heart Failure and Anemia with Reference to Iron Metabolism Markers in an Adult Woman.

Authors:  Yuya Nakamura; Isao Ohsawa; Yoshikazu Goto; Hokuto Namba; Yusuke Dodo; Mayumi Tsuji; Yuji Kiuchi; Masahiro Inagaki; Hiromichi Gotoh
Journal:  Intern Med       Date:  2017-11-01       Impact factor: 1.271

10.  Myopericarditis and exertional rhabdomyolysis following an influenza A (H3N2) infection.

Authors:  Guo-Shiang Tseng; Chung-Yueh Hsieh; Ching-Tsai Hsu; Jung-Chung Lin; Jenq-Shyong Chan
Journal:  BMC Infect Dis       Date:  2013-06-21       Impact factor: 3.090

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.